Literature DB >> 30072583

miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4.

Anna Prossomariti1,2, Giulia Piazzi3,2, Leonarda D'Angelo2, Sara Miccoli4,5, Daniela Turchetti4,5, Chiara Alquati1,2, Claudio Montagna1,2, Franco Bazzoli1, Luigi Ricciardiello3,2,5.   

Abstract

Adenomatous Polyposis Coli (APC) gene mutations are responsible for the onset of familial adenomatous polyposis (FAP) and sporadic colorectal cancer and have been associated with miRNAs dysregulation. The capacity of miR-155, a cancer-related miRNA, to target components of the WNT/β-CATENIN pathway suggests that APC gene mutations, controlling miRNAs expression, may critically regulate WNT/β-CATENIN signaling. To this end, APC gene target sequencing was performed on colonic adenomatous polyps and paired normal mucosa clinical specimens from FAP patients (n = 9) to elucidate the role of miR-155-5p in APC-mutant setting. The expression of selected miRNAs and WNT/β-CATENIN signaling components was characterized in FAP patients and non-FAP control subjects (n = 5). miR-155-5p expression and functional effects on WNT cascade, cell survival, growth, and apoptosis were investigated in different colorectal cancer cell lines. A somatic second hit in the APC gene was found in adenomatous polyps from 6 of 9 FAP patients. Heterozygous APC gene mutations in FAP patients were associated with altered expression of candidate miRNAs and increased levels of AXIN1 and AXIN2 mRNAs. miR-155-5p was downregulated in FAP patients and in the APC and β-CATENIN-mutant colorectal cancer cell lines, and critically regulates WNT/β-CATENIN cascade by targeting both AXIN1 and TCF4. Importantly, miR-155-5p may sustain long-term WNT/β-CATENIN activation in colorectal cancer cells upon WNT3A stimulation. IMPLICATIONS: This study supports a key role of miR-155-5p in modulating WNT/β-CATENIN signaling in colorectal cancer and unravels a new mechanism for AXIN1 regulation which represents a potential therapeutic target in specific tumor subtypes. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30072583     DOI: 10.1158/1541-7786.MCR-18-0115

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

1.  Study of KRAS-Related miRNA Expression in Colorectal Cancer.

Authors:  Xiaobing Wu; Zhifa Li; Nanqi Huang; Xiaodan Li; Rong Chen
Journal:  Cancer Manag Res       Date:  2022-10-17       Impact factor: 3.602

2.  Axin1 inhibits proliferation, invasion, migration and EMT of hepatocellular carcinoma by targeting miR-650.

Authors:  Ancheng Qin; Jianwu Wu; Min Zhai; Yijie Lu; Bo Huang; Xingsheng Lu; Xinwei Jiang; Zhiming Qiao
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  MiR-155 promotes colitis-associated intestinal fibrosis by targeting HBP1/Wnt/β-catenin signalling pathway.

Authors:  Nianshuang Li; Yaobin Ouyang; Xinbo Xu; Zhenxiang Yuan; Chunquan Liu; Zhenhua Zhu
Journal:  J Cell Mol Med       Date:  2021-03-26       Impact factor: 5.310

Review 4.  MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer.

Authors:  Fangfang Yang; Guoyun Xuan; Yixin Chen; Lichao Cao; Min Zhao; Chen Wang; Erfei Chen
Journal:  Front Cell Dev Biol       Date:  2022-04-08

5.  KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.

Authors:  Feng Du; Tianyu Cao; Huahong Xie; Ting Li; Lina Sun; Hao Liu; Hao Guo; Xin Wang; Qi Liu; Taewan Kim; Jeffrey L Franklin; Ramona Graves-Deal; Weili Han; Zuhong Tian; Minghui Ge; Yongzhan Nie; Daiming Fan; Robert J Coffey; Yuanyuan Lu; Xiaodi Zhao
Journal:  Theranostics       Date:  2020-06-05       Impact factor: 11.556

6.  Overexpression of microRNA‑155 alleviates palmitate‑induced vascular endothelial cell injury in human umbilical vein endothelial cells by negatively regulating the Wnt signaling pathway.

Authors:  Yanping Zhao; Wenquan Rao; Yanna Wan; Xinglong Yang; Guorong Wang; Jun Deng; Min Dai; Qiang Liu
Journal:  Mol Med Rep       Date:  2019-08-27       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.